Moreover, the loss of BRG1 expression, which can be detected by immunohistochemistry with an anti-BRG1 antibody, is associated with SMARCA4 class I mutations, and was found to be predominantly detected in adenocarcinomas with co-occurring mutations in KRAS, STK11, TP53 and KEAP1 [105]. The gene discussed is SMARCA4; the disease is adenocarcinoma.